Rep. Kevin Hern Unloads Shares of Medtronic PLC (NYSE:MDT)

Key Points

• Rep. Kevin Hern sold $15,001–$50,000 of Medtronic shares on August 24, 2026, through the Hern Family Foundation account. He also sold holdings in several other companies, including Home Depot, Procter & Gamble, Microsoft and Honeywell Aerospace.
• Medtronic reported quarterly adjusted earnings of $1.45 per share and revenue of $9.76 billion, beating analyst estimates; revenue rose 13.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $102.96.
• The company declared a quarterly dividend of $0.72 per share, equivalent to $2.88 annually and a 3.1% yield. The dividend is payable October 16 to shareholders of record as of September 25.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC NYSE: MDT. In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on August 24th. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Home Depot NYSE: HD on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Procter & Gamble NYSE: PG on 8/24/2026.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Veralto NYSE: VLTO on 8/21/2026.
• Sold $15,001 - $50,000 in shares of Honeywell Aerospace NASDAQ: HONA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Colgate-Palmolive NYSE: CL on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Biogen NASDAQ: BIIB on 8/18/2026.
• Sold $1,001 - $15,000 in shares of Anheuser-Busch InBev SA/NV NYSE: BUD on 8/18/2026.

Medtronic Stock Performance

NYSE MDT opened at $92.10 on Thursday. The firm has a market capitalization of $117.89 billion, a P/E ratio of 22.69, a price-to-earnings-growth ratio of 2.15 and a beta of 0.56. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The firm's fifty day moving average price is $86.27 and its two-hundred day moving average price is $85.35. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. Medtronic's revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.96 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic's dividend payout ratio is 77.21%.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm's stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company's stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MDT. Jefferies Financial Group reiterated a "hold" rating and issued a $88.00 price target on shares of Medtronic in a research note on Thursday, June 4th. TD Cowen raised their price objective on shares of Medtronic from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, August 28th. Leerink Partners reduced their price objective on Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a report on Thursday, June 4th. Mizuho set a $115.00 target price on Medtronic in a research report on Wednesday. Finally, Wall Street Zen upgraded Medtronic from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $102.96.

Institutional Trading of Medtronic

A number of institutional investors and hedge funds have recently made changes to their positions in MDT. Madison Asset Management LLC lifted its holdings in shares of Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company's stock worth $18,752,000 after acquiring an additional 25,527 shares during the last quarter. First Eagle Investment Management LLC boosted its position in Medtronic by 0.4% in the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company's stock valued at $939,009,000 after buying an additional 40,196 shares in the last quarter. Gradient Investments LLC boosted its position in Medtronic by 3.9% in the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company's stock valued at $38,842,000 after buying an additional 18,509 shares in the last quarter. Czech National Bank grew its stake in shares of Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company's stock worth $28,589,000 after buying an additional 16,292 shares during the last quarter. Finally, Cerity Partners LLC grew its stake in shares of Medtronic by 12.7% during the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company's stock worth $75,988,000 after buying an additional 89,111 shares during the last quarter. Institutional investors own 82.06% of the company's stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
• Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
• Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
• Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
• Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source